Company Filing History:
Years Active: 2008
Title: Junro Kuromitsu: Innovator in Cancer Treatment
Introduction
Junro Kuromitsu is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of cancer research, particularly in the development of methods for testing anticancer agent sensitivity in tumor cells. His innovative approach aims to improve treatment outcomes for cancer patients.
Latest Patents
Junro Kuromitsu holds a patent for a method of testing anticancer agent sensitivity of tumor cells. This patent describes a process where the susceptibility of a tumor cell to an anticancer agent is assessed by measuring the expression levels of specific genes in tumor cells collected from cancer patients. The method involves determining the effectiveness of the anticancer agent E7070 and related compounds by analyzing gene expression changes, which can indicate whether a tumor cell is susceptible to treatment. He has 1 patent in this area.
Career Highlights
Kuromitsu is associated with Eisai Company, Limited, a leading pharmaceutical company known for its commitment to developing innovative cancer therapies. His work at Eisai has positioned him as a key player in the ongoing fight against cancer, contributing to advancements that could potentially save lives.
Collaborations
Throughout his career, Junro Kuromitsu has collaborated with esteemed colleagues such as Takashi Owa and Akira Yokoi. These partnerships have fostered a collaborative environment that enhances research and development efforts in the field of oncology.
Conclusion
Junro Kuromitsu's contributions to cancer research through his innovative patent and work at Eisai Company, Limited highlight his dedication to improving patient outcomes. His efforts in testing anticancer agent sensitivity represent a significant advancement in the fight against cancer.